Immuno-Oncology Clinical Network @IOClinicalNet

🩷 Supporting Education Across the UK As part of #CancerImmunotherapyMonth, we're proud to highlight educational initiatives that are supported and endorsed by the Immuno-Oncology Clinical Network (IOCN). We believe that improving patient outcomes begins with supporting healthcare professionals through accessible, high-quality education and shared learning. The IOCN are proud to support and endorse: 🎓 National IO Education Forum A free monthly national virtual education meeting bringing together approximately 100 multidisciplinary healthcare professionals involved in immunotherapy care from across the UK. 🎙️ The Immunobuddies An innovative educational platform translating complex immunotherapy science into practical, real-world learning. Find out more below. Together, these initiatives help strengthen education, collaboration and patient care across the immuno-oncology community. Supporting those receiving immunotherapy by supporting those delivering it. #ImmunotherapyAwarenessMonth #IOCN #Education #Immunotherapy #SharedLearning #CancerCare #Immunobuddies #NationalIOEducationForum @AOlssonBrown @RickyFrazer1 @JohnsonA_D @DTM_xx @Nick_G89 @brentocarrigan @will_oncology @Youngdr100 @TrudyGuinan @UKONSmember @BOPACommittee @OncoDailyIO @ACPUK @myESMO @ASCO @oncologyforum @OncologyNT @simplyoncology

🩷 Education in Action As part of #CancerImmunotherapyMonth, we're highlighting the IOCN's commitment to education and shared learning. Through our growing educational programme, we aim to support healthcare professionals delivering immunotherapy by providing practical, relevant and accessible learning opportunities. Our webinar series include: ❓ Ask A Question Interactive monthly webinars where cases and questions are discussed by an expert panel. 💡 New & Novel Exploring emerging immunotherapies and associated toxicities, including CRS, HLH and ICANS. 🌟 Spotlight Featuring cutting-edge developments, expert insights and practical approaches in immuno-oncology. 🏥 Service Showcase Showcasing innovative immunotherapy services and best practice from across the UK. In addition, we host two face-to-face "Advance the Management of Immunotherapy Toxicities Through Case Conundrums" study days each year, bringing together multidisciplinary colleagues from across the UK to discuss complex clinical cases and share learning. We are also proud to support and promote educational initiatives delivered by colleagues and partner organisations nationwide. Discover more about all our education offerings and register via our website: ioclinicalnetwork.co.uk/education-and-… Together, we are building a connected and informed immuno-oncology community. #ImmunotherapyAwarenessMonth #IOCN #Immunotherapy #Education #CancerCare #SharedLearning @AOlssonBrown @RickyFrazer1 @JohnsonA_D @DTM_xx @Nick_G89 @brentocarrigan @will_oncology @Youngdr100 @TrudyGuinan @UKONSmember @BOPACommittee @OncoDailyIO @ACPUK @myESMO @ASCO @oncologyforum @OncologyNT @simplyoncology

🟢 Clinical Support in Development As part of #ImmunotherapyAwarenessMonth, we're highlighting ongoing work within the Immuno-Oncology Clinical Network (IOCN) aimed at supporting healthcare professionals managing immune-related adverse events (irAEs). Two new guidance documents are currently in development: 🦠 Antimicrobial prophylaxis for patients receiving immunosuppression Providing practical recommendations to support infection prevention in patients requiring immunosuppressive therapies for the management of immunotherapy toxicities. 🦴 Bone protection guidance for patients receiving steroids in response to immunotherapy toxicities Supporting best practice to reduce the risk of steroid-induced bone loss and associated complications. These projects are being developed through multidisciplinary collaboration and reflect the IOCN's commitment to providing practical, evidence-informed resources to support healthcare professionals and improve patient care. More information will be shared as these projects progress. #ImmunotherapyAwarenessMonth #IOCN #Immunotherapy #ClinicalSupport #PatientSafety #irAEs @AOlssonBrown @RickyFrazer1 @JohnsonA_D @DTM_xx @Nick_G89 @brentocarrigan @will_oncology @Youngdr100 @TrudyGuinan @UKONSmember @BOPACommittee @OncoDailyIO @ACPUK @myESMO @ASCO @oncologyforum @OncologyNT @simplyoncology

📍 We’re excited to be exhibiting at the UK Oncology Forum 2026 at the Harrogate Convention Centre! If you're attending, be sure to visit the Immuno-Oncology Clinical Network (IOCN) exhibition stand to learn more about our work supporting healthcare professionals in the delivery of immunotherapy services and the management of immune-related adverse events. 👋 Come and say hello, meet the team, and discover how the IOCN is helping to connect, educate, and support the oncology community across the UK. We look forward to seeing colleagues, sharing ideas, and building new collaborations throughout the conference. #UKOncologyForum2026 #UKOF26 #IOCN #ImmunoOncology #CancerCare #OncologyNursing #CancerServices #Collaboration #Harrogate #OncologyCommunity @AOlssonBrown @DTM_xx @Nick_G89 @immunobuddies

🫀 Advancing Cardio-Oncology As part of hashtag#CancerImmunotherapyMonth, we're highlighting the collaborative work of the Immuno-Oncology Clinical Network (IOCN) in improving the recognition and management of immune-related cardiac toxicities. In 2024, the IOCN, in collaboration with the British Cardio-Oncology Society (BCOS), published the Joint Consensus Statement: 📖 Baseline Cardiac Assessment in Individuals Receiving Immune Checkpoint Inhibitors The document provides practical recommendations to support clinicians in implementing baseline cardiac assessment and promoting consistent, evidence-informed practice across the UK. Building on this work, a multidisciplinary working group is currently developing a further consensus statement focused on the management of immune-related cardiac toxicities. 🫀 Expected release: Autumn/Winter 2026 Through continued collaboration between oncology and cardiology specialists, we aim to strengthen patient safety, improve outcomes and support healthcare professionals delivering immunotherapy. Together, we are helping shape the future of cardio-oncology. #ImmunotherapyAwarenessMonth #IOCN #CardioOncology #PatientSafety #Immunotherapy #CancerCare #UKOF26 #BCOS @AOlssonBrown @RickyFrazer1 @JohnsonA_D @DTM_xx @Nick_G89 @brentocarrigan @will_oncology @Youngdr100 @TrudyGuinan @UKONSmember @BOPACommittee @OncoDailyIO @ACPUK @myESMO @ASCO @oncologyforum @OncologyNT @simplyoncology

🟡 Building a National Framework for irAE Management As part of #CancerImmunotherapyMonth, we're highlighting ongoing work being led through the Immuno-Oncology Clinical Network (IOCN). Following concerns regarding inequitable access to immunosuppressive medicines used in the management of immune checkpoint inhibitor (ICI) toxicities, the IOCN and UKSACT Board engaged with NHS England in November 2025 to discuss the challenges faced across the UK. This work led to the establishment of a national multidisciplinary working group tasked with developing a consensus framework for the comprehensive management of immune-related adverse events (irAEs). In May 2026, experts from across the UK came together at the IOCN two-day meeting in London to begin shaping this work through a series of collaborative workshops. Our shared aim is to ensure that patients receive the greatest possible benefit from immunotherapy while reducing the risk of serious toxicity and treatment-related complications through consistent, evidence-informed pathways of care. By working together nationally, we hope to: 🟡 Improve equity of access 🟡 Strengthen patient safety 🟡 Improve patient outcome 🟡 Support healthcare professionals delivering immunotherapy 🟡 Promote consistent, evidence-informed management of irAEs ✍ We are now bringing together the outputs from these workshops to begin developing a proposed consensus framework. Together, we are helping shape the future of immunotherapy toxicity management. #ImmunotherapyAwarenessMonth #IOCN #irAEs #PatientSafety #ImmunoOncology #PolicyAndGovernance #UKOF26 @AOlssonBrown @RickyFrazer1 @JohnsonA_D @DTM_xx @Nick_G89 @brentocarrigan @will_oncology @Youngdr100 @TrudyGuinan @UKONSmember @BOPACommittee @OncoDailyIO @ACPUK @myESMO @ASCO @oncologyforum @OncologyNT @simplyoncology

🤝 Collaboration in Action As part of #CancerImmunotherapyMonth, we're highlighting some of the work delivered through the Immuno-Oncology Clinical Network (IOCN). In collaboration with the BOPA (The British Oncology Pharmacy Association), we have developed a series of second-line agent drug monographs to support healthcare professionals in the prescribing and monitoring of immunosuppressive therapies used in the management of immune-related adverse events (irAEs) caused by immune checkpoint inhibitors. 📖 Eleven monographs are now available covering: • Abatacept • Anakinra • Budesonide • Infliximab • Intravenous Immunoglobulin (IVIg) • Methotrexate • Mycophenolate Mofetil (MMF) • Rituximab • Tacrolimus • Tocilizumab • Vedolizumab These resources form part of our commitment to supporting healthcare professionals delivering immuno-oncology therapies and improving patient care. 🚨 More monographs will be released in the coming months. Access the resources here: ioclinicalnetwork.co.uk/clinical-suppo… #ImmunotherapyAwarenessMonth #IOCN #BOPA #ImmunoOncology #CancerCare #ClinicalSupport #Immunotherapy #UKOF26 @AOlssonBrown @RickyFrazer1 @JohnsonA_D @DTM_xx @Nick_G89 @brentocarrigan @will_oncology @Youngdr100 @TrudyGuinan @UKONSmember @BOPACommittee @OncoDailyIO @ACPUK @myESMO @ASCO @oncologyforum @OncologyNT @simplyoncology

@AOlssonBrown @RickyFrazer1 @JohnsonA_D @DTM_xx @Nick_G89 @brentocarrigan @will_oncology @Youngdr100 @TrudyGuinan @UKONSmember @BOPACommittee @OncoDailyIO @ACPUK @myESMO @ASCO @oncologyforum @OncologyNT @simplyoncology #ImmunotherapyAwarenessMonth #CancerImmunotherapyMonth #ImmunoOncology #CancerCare #IOCN #OncologyForum #UKOF26

🚨 BREAKING – Registration is NOW OPEN Join us for the next instalment of the hugely popular "Advancing the Management of Immunotherapy Toxicities Through Case Conundrums" conference! 📅 Friday 16th October 2026 📍 Vermont Hotel, Newcastle-Upon-Tyne 💷 £150pp This CPD-accredited event brings together experts and healthcare professionals to explore real-world immunotherapy toxicity cases, share best practice, and learn through interactive discussion. ✅ 6.5 hours CPD ✅ Expert-led sessions ✅ Cutting-edge topics ✅ Interactive learning & networking ✨ Got a case to share? Abstract submissions are now open – this is your chance to showcase your experience and contribute to advancing IO toxicity management. 📝 Deadline: Friday 11th September 2026 👉 Secure your place or submit your abstract via the link/QR code tinyurl.com/r3shtef4 @AOlssonBrown @RickyFrazer1 @JohnsonA_D @Youngdr100 @will_oncology @brentocarrigan @alihodge @DTM_xx @Nick_G89 @tjg0596 @TrudyGuinan @NorthernCancer @OncoDailyIO @OncoDailyGI @OncoViews @ACPUK @RCPhysicians @immunobuddies @BOPACommittee @UKONSmember @UKASCC @BCOSCardioOnc @oncologyNT @myESMO @ASCO @OncEd @oncologyTimes @simplyoncology @onctrainees @oncology #IOCN #Immunotherapy #Oncology #HealthcareEducation #MedEd #CancerCare #irAEs #CPD

keyboard_arrow_left Previous keyboard_arrow_right Next

Day 2 of the Immuno-Oncology Clinical Network national meeting in London continues with productive discussions focused on shaping a National Framework for the comprehensive management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor immunotherapies. Over the past two days, Clinicians Pharmacists and Nurses from across the UK have collaborated to share expertise, identify priorities, and explore how we can deliver safer, more consistent care for patients receiving immunotherapy treatments. Our collective goal remains clear: to maximise the benefits of immunotherapy while reducing the risk of serious toxicity and improving outcomes for patients nationwide. Thank you to everyone contributing their time, expertise, and commitment to this important work. #Immunotherapy #ImmunoOncology #PatientSafety #CancerCare #irAEs #HealthcareCollaboration #Oncology #IOCN @AOlssonBrown @Youngdr100 @JohnsonA_D @UKONSmember @BOPACommittee @immunobuddies @nhsEngland @nhs

keyboard_arrow_left Previous keyboard_arrow_right Next

The Immuno-Oncology Clinical Network 2-day meeting in London is now underway, bringing together experts from across the UK to discuss the development of a National Framework for the comprehensive management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor immunotherapies. Our shared aim is to ensure that patients can achieve the greatest possible benefit from these transformative treatments, while reducing the risk of serious toxicity and treatment-related complications through consistent, evidence-informed care pathways. By collaborating nationally, we hope to strengthen patient safety, improve outcomes, and support healthcare teams in delivering high-quality immunotherapy toxicity management. #Immunotherapy #ImmunoOncology #PatientSafety #CancerCare #irAEs #HealthcareCollaboration #Oncology #IOCN @UKONSmember @BOPACommittee @immunobuddies

keyboard_arrow_left Previous keyboard_arrow_right Next

Where will the next Immuno-Oncology Clinical Network Case Conundrums take us…? 👀 We’re hitting the road again for the next instalment of challenging cases, shared learning and immuno-oncology discussion — but there’s just one question… 📍 Which city is next? Watch the big reveal below! 🎥👇 Registration will open soon! #IOCN #CaseConundrum #ImmunoOncology #CancerCare #MedicalEducation #HealthcareEvents #Oncology #ComingSoon @AOlssonBrown @RickyFrazer1 @immunobuddies @UKONSmember @BOPACommittee

The debates have started… current session on all things reading infectious diseases and toxicity’s and the use of immunosuppressants with @AOlssonBrown @RickyFrazer1 and Dr Jonathan underwood #casecondundrums

First talk after lunch… Dr Nima Ghadiri and IOCN trustee Dr Clare Barlow regarding ocular toxicities management #casecondundrums #iocn @AOlssonBrown @RickyFrazer1

Great poster presentation from our winning poster author Elsbeth Nye. Elsbeth presented her poster which looked at isolated immune related proctotis complicated by latent tuberculosis. Congratulations Elsbeth 👏…more to come on the rest of the award winners. #casecondundrums @AOlssonBrown @RickyFrazer1

The third session of the day was our very own @AOlssonBrown and nurse consultant and IOCN trustee Ali Hodge looking at multiple and recurrent toxicities case study’s @immunobuddies #iocn #caseconundrums

The obligatory Case Conundrums selfie with our fantastic colleagues from across the UK! @AOlssonBrown @RickyFrazer1 #caseconundrums

Second session with Dr Cleo Solomon and Dr Peter hill discussing all things renal toxicities @AOlssonBrown @RickyFrazer1 @immunobuddies #caseconundrums

First session of the day on neorological toxicities with experts Dr Mark Willis and Dr Ben Schroeder thank you both for joining us @AOlssonBrown @RickyFrazer1 @immunobuddies #caseconundrums